Description
Description
More than 300 million people in the world are suffering from seasonal asthma of varying degrees. The number is higher in countries with severe environmental pollution and high tobacco consumption. Asthma and allergic rhinitis are common nowadays. Owing to heavy air pollution, the incidences of these diseases are increasing year by year.
Montelukast, developed by MSD, is widely used in the treatment of allergic rhinitis and asthma. As a selective leukotriene D4 receptor antagonist, it selectively binds to the leukotrienes in the airway, blocks the action of allergic mediators, reduces airway inflammation, and makes the airway unobstructed. In 1998, Montelukast sodium tablets (10 mg) and chewable tablets (5 mg) were approved by the FDA and first marketed in the U.S. in the trade name of “Singulair”. In 2000 and 2002, Montelukast chewable tablets (4 mg) and granules (4 mg) were approved for sale, mainly for the prevention and long-term treatment of asthma in adults and children aged above 2.
In 1999, MSD’s Montelukast chewable tablets (5mg) and tablets (10mg) were approved to enter China in the trade name of “Singulair”, followed by Montelukast chewable tablets (4mg) and granules (4mg). In 2006, the generic Montelukast tablets (10mg) and chewable tablets (5mg) by Sichuan Otsuka Pharmaceutical Co., Ltd. were approved to be sold in the trade name of “Bystine”. Many other companies in China have also filed applications for generic Montelukast.
According to CRI’s market research, from 2005 to 2010, the annual sales value of Montelukast in China grew at a CAGR of more than 40%. As competing products emerged, the growth rate slowed down from 2011 but stays above 10%. In 2017, the market size of Montelukast was about CNY 552 million. The market was dominated by MSD, Lunan Better Pharmaceutical Co., Ltd., and Sichuan Otsuka Pharmaceutical Co., Ltd. Declining in recent years, the market share by sales value of MSD was close to 73%.
According to statistics, there are more than 30 million asthma patients and 300 million to 400 million patients with allergic rhinitis in China. And the numbers will continue to rise with increasingly serious environmental pollution. In China, Montelukast is considered as one of the best anti-asthmatic drugs, which promises huge market potential.
Topics Covered:
– Situation of respiratory diseases in China
– Supply and sales of Montelukast in China
– Prices of Montelukast in China
– Competition on China’s Montelukast market
– Market share of Montelukast manufacturers in China
– Prospect of China’s Montelukast Market, 2018-2022
